<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39336857</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Non-Conventional Prognostic Markers in Life-Threatening COVID-19 Cases-When Less Is More.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5369</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13185369</ELocationID><Abstract><AbstractText><b>Background/Objectives</b>: In this study, we aimed to compare the predictive power of non-conventional (neutrophil/lymphocyte ratio-NLR; platelet/lymphocyte ratio-PLR) and conventional markers (C-reactive protein-CRP; procalcitonin-PCT; interleukin-6-IL-6) in terms of disease progression and mortality in severe SARS-CoV-2 patients. <b>Methods</b>: In this prospective observatory study, blood samples were collected daily, focusing on the established inflammatory markers. Critically ill COVID-19 patients who required ICU admission were included. Patient treatment followed established COVID-19 protocols, and the data analysis was performed using SPSS with non-normal distribution methods. The study cohort primarily included patients infected with the delta variant. <b>Results</b>: A mortality rate of 76.6% was observed among 167 patients during the study period. Significant differences in conventional and non-conventional markers between survivor and non-survivor groups were observed. The PCT levels were significantly elevated (<i>p</i> &lt; 0.005) in the deceased group. Among the non-conventional markers, the NLR was consistently higher in non-survivors and emerged as a significant predictor of mortality, whereas the PLR was not elevated among the non-survivors. ROC analyses indicated that PCT and the NLR were the markers with the highest predictive power for mortality. The multivariate logistic regression analysis identified NLR, PCT, CRP, and IL-6 as significant predictors of mortality across different days. The NLR showed a consistent, though not always statistically significant, association with increased mortality risk, particularly on Days 2 and 5. <b>Conclusions</b>: The NLR's accessibility and simplicity of determination make it a valuable and practical tool for monitoring inflammatory processes in viral infections. Our findings suggest that incorporating NLR analysis into routine clinical practice could enhance the early identification of high-risk patients, thereby improving patient management and outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rozanovic</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3800-4096</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Várady-Szabó</LastName><ForeName>Kata</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domokos</LastName><ForeName>Kamilla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiss</LastName><ForeName>Tamás</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loibl</LastName><ForeName>Csaba</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Márovics</LastName><ForeName>Gergely</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4382-0554</Identifier><AffiliationInfo><Affiliation>Department of Public Health Medicine, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rendeki</LastName><ForeName>Szilárd</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5997-617X</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Csontos</LastName><ForeName>Csaba</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, University of Pécs Medical School, 7624 Pécs, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TKP2021-NVA-06</GrantID><Agency>National Research, Development, and Innovation Fund of Hungary</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">hemorheology</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">neutrophil/lymphocyte ratio</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the study’s design; in the collection, analysis, or interpretation of the data; in manuscript writing; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336857</ArticleId><ArticleId IdType="pmc">PMC11432304</ArticleId><ArticleId IdType="doi">10.3390/jcm13185369</ArticleId><ArticleId IdType="pii">jcm13185369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N. Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130–137. doi: 10.1111/resp.13196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.13196</ArticleId><ArticleId IdType="pmc">PMC7169239</ArticleId><ArticleId IdType="pubmed">29052924</ArticleId></ArticleIdList></Reference><Reference><Citation>Temperton N.J., Chan P.K., Simmons G., Zambon M.C., Tedder R.S., Takeuchi Y., Weiss R.A. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 2005;11:411–416. doi: 10.3201/eid1103.040906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1103.040906</ArticleId><ArticleId IdType="pmc">PMC3298259</ArticleId><ArticleId IdType="pubmed">15757556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang D.H., Kim G.H.J., Park S., Lee S., Koh J.S., Brown M.S., Abtin F., Mcnitt-gray M.F., Goldin J.G., Lee J.S. Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with. Biomedicines. 2024;12:120. doi: 10.3390/biomedicines12010120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12010120</ArticleId><ArticleId IdType="pmc">PMC10813449</ArticleId><ArticleId IdType="pubmed">38255225</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Liu S., Liu J., Zhang Z., Wan X., Huang B., Chen Y., Zhang Y. COVID-19: Immunopathogenesis and Immunotherapeutics. Signal Transduct. Target. Ther. 2020;5:128. doi: 10.1038/s41392-020-00243-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00243-2</ArticleId><ArticleId IdType="pmc">PMC7381863</ArticleId><ArticleId IdType="pubmed">32712629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021;93:250–256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Li W., Drabek D., Okba N.M.A., van Haperen R., Osterhaus A.D.M.E., van Kuppeveld F.J.M., Haagmans B.L., Grosveld F., Bosch B.J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020;11:2251. doi: 10.1038/s41467-020-16256-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16256-y</ArticleId><ArticleId IdType="pmc">PMC7198537</ArticleId><ArticleId IdType="pubmed">32366817</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti N., Lalezari J.P., Amodeo P.P., Mody K., Mosher S.F., Seethamraju H., Kelly S.A., Pourhassan N.Z., Sudduth C.D., Bovinet C., et al. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. J. Transl. Autoimmun. 2021;4:100083. doi: 10.1016/j.jtauto.2021.100083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100083</ArticleId><ArticleId IdType="pmc">PMC7823045</ArticleId><ArticleId IdType="pubmed">33521616</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton F., Confalonieri P., Campisciano G., Cifaldi R., Rizzardi C., Generali D., Pozzan R., Tavano S., Bozzi C., Lapadula G., et al. Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS. J. Clin. Med. 2022;11:2951. doi: 10.3390/jcm11112951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11112951</ArticleId><ArticleId IdType="pmc">PMC9180983</ArticleId><ArticleId IdType="pubmed">35683340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., Chakraborti S., He Y., Roberts A., Sheahan T., Xiao D., Hensley L.E., Prabakaran P., Rockx B., Sidorov I.A., et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 2007;104:12123–12128. doi: 10.1073/pnas.0701000104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0701000104</ArticleId><ArticleId IdType="pmc">PMC1924550</ArticleId><ArticleId IdType="pubmed">17620608</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Xie X., Tu Z., Fu J., Xu D., Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 2021;6:255. doi: 10.1038/s41392-021-00679-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.D., Parajuli A., Gale H.J., Bulteel N.S., Schuetz P., de Jager C.P.C., Loonen A.J.M., Merekoulias G.I., Baillie J.K. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis. J. Infect. 2019;78:339–348. doi: 10.1016/j.jinf.2019.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2019.02.006</ArticleId><ArticleId IdType="pmc">PMC7173077</ArticleId><ArticleId IdType="pubmed">30802469</ArticleId></ArticleIdList></Reference><Reference><Citation>Curbelo J., Rajas O., Arnalich B., Galván-Román J.M., Luquero-Bueno S., Ortega-Gómez M., Lancho A., Roy E., Sánchez Azofra A., Mateo Jiménez G., et al. Neutrophil Count Percentage and Neutrophil–Lymphocyte Ratio as Prognostic Markers in Patients Hospitalized for Community-Acquired Pneumonia. Arch. Bronconeumol. 2019;55:472–477. doi: 10.1016/j.arbres.2019.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2019.02.005</ArticleId><ArticleId IdType="pubmed">30914210</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., Qi D., Yuan G., Deng X., Mei Y., Feng L., Wang D. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): A multicenter, cross-sectional study. J. Clin. Lab. Anal. 2020;34:e23475. doi: 10.1002/jcla.23475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23475</ArticleId><ArticleId IdType="pmc">PMC7404368</ArticleId><ArticleId IdType="pubmed">32681559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagunas-Rangel F.A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J. Med. Virol. 2020;92:1733–1734. doi: 10.1002/jmv.25819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25819</ArticleId><ArticleId IdType="pmc">PMC7228336</ArticleId><ArticleId IdType="pubmed">32242950</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu R., Ling Y., Zhang Y., Wei L., Chen X., Li X., Liu X., Liu H., Guo Z., Ren H., et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J. Med. Virol. 2020;92:1533–1541. doi: 10.1002/jmv.25767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25767</ArticleId><ArticleId IdType="pmc">PMC7228291</ArticleId><ArticleId IdType="pubmed">32181903</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund O., Weiss T.E., Tau L., Meidan R., Liron Y., Tchebiner Z., Bornstein G. Safety and outcomes of an early discharge strategy with oxygen home therapy in stable severe COVID-19 patients. Infect. Dis. 2023;55:292–298. doi: 10.1080/23744235.2023.2168047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2023.2168047</ArticleId><ArticleId IdType="pubmed">36645149</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu C., Mao Z., Xiao M., Wang L., Qi S., Zhou F. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis. Crit. Care. 2020;24:647. doi: 10.1186/s13054-020-03374-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03374-8</ArticleId><ArticleId IdType="pmc">PMC7667659</ArticleId><ArticleId IdType="pubmed">33198786</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Li L., Da X.M., Wu J., Luo D., Zhu Y.S., Li B.X., Song X.Y., Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol. 2020;127:104370. doi: 10.1016/j.jcv.2020.104370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104370</ArticleId><ArticleId IdType="pmc">PMC7194648</ArticleId><ArticleId IdType="pubmed">32344321</ArticleId></ArticleIdList></Reference><Reference><Citation>Damar Çakırca T., Torun A., Çakırca G., Portakal R.D. Role of NLR, PLR, ELR and CLR in differentiating COVID-19 patients with and without pneumonia. Int. J. Clin. Pract. 2021;75:2–7. doi: 10.1111/ijcp.14781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14781</ArticleId><ArticleId IdType="pmc">PMC8646493</ArticleId><ArticleId IdType="pubmed">34482573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponti G., Maccaferri M., Ruini C., Tomasi A., Ozben T. Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci. 2020;57:389–399. doi: 10.1080/10408363.2020.1770685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1770685</ArticleId><ArticleId IdType="pmc">PMC7284147</ArticleId><ArticleId IdType="pubmed">32503382</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz T., Holbik J., Grieb A., Karolyi M., Hind J., Gibas G., Neuhold S., Zoufaly A., Wenisch C. The Role of Bacterial and Fungal Superinfection in Critical COVID-19. Viruses. 2022;14:2785. doi: 10.3390/v14122785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122785</ArticleId><ArticleId IdType="pmc">PMC9783059</ArticleId><ArticleId IdType="pubmed">36560789</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>